Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and ... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In ... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Phase II Open-label Study Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopha... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137 ... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Evaluating the Clinical and Economic Outcomes of Adding Semaglutide to Standard of Care in Adult P... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Int... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Platelet-Rich Plasma with Hyaluronic Acid Injections for Post- Viral Olfactory loss. A double-blin... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Leveraging AS01-induced immune cell reprogramming to modulate immune dysregulation in rheumatoid a... Read More